NCT05258708 is a clinical trial of mRNA-1273 COVID-19 vaccine in COVID-19, sponsored by Korea University Guro Hospital.

Who is sponsoring NCT05258708?

NCT05258708 is sponsored by Korea University Guro Hospital.

What drugs are being tested in NCT05258708?

Interventions in NCT05258708: mRNA-1273 COVID-19 vaccine.

What condition does NCT05258708 study?

NCT05258708 studies COVID-19, Vaccine Immune Response, Vaccine Adverse Reaction.

Is NCT05258708 still recruiting?

NCT05258708 is currently status unknown. Last updated 28 February 2022.

Last reviewed 2022-02-28 · How we verify

NCT05258708

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Vaccine Reactogenicity and Immunogenicity

Status unknown Last updated 28 February 2022

What this trial tests

trial testing mRNA-1273 COVID-19 vaccine in COVID-19 in 179 participants. Status unknown.

Timeline

24 June 2021

Primary endpoint
30 May 2022

30 May 2022

Quick facts

Lead sponsor	Korea University Guro Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	179
Start date	24 June 2021
Primary completion	30 May 2022
Estimated completion	30 May 2022
Sites	5 locations across South Korea

Drugs / interventions tested

mRNA-1273 COVID-19 vaccine — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Vaccine Immune Response — all drugs for Vaccine Immune Response →
Vaccine Adverse Reaction — all drugs for Vaccine Adverse Reaction →

Sponsor

Korea University Guro Hospital

Who can join

Adults 19 to 55, any sex, with COVID-19 or Vaccine Immune Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analysis of antibody kinetics after vaccination with mRNA-1273 and factors influencing the vaccine immunogenicity

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity.
Choi MJ, Heo JY, Seo YB, Yoon YK, et al · · 2022 · cited 6× · PMID 36700198 · DOI 10.3389/fimmu.2022.1035441
Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study.
Choi MJ, Heo JY, Seo YB, Yoon YK, et al · · 2023 · cited 6× · PMID 36679965 · DOI 10.3390/vaccines11010120
Predictive value of reactogenicity for anti-SARS-CoV-2 antibody response in mRNA-1273 recipients: a multicenter prospective cohort study
Choi MJ, Heo JY, Seo YB, Yoon YK, et al · · 2022 · DOI 10.21203/rs.3.rs-1622167/v1

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Korea University Guro Hospital trials

Trials by the same sponsor.

NCT07009769 — AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy · completed
NCT06752733 — Cardiac Stunning After Electrical Cardioversion · active not recruiting
NCT06202690 — SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC · NA · not yet recruiting
NCT06889259 — Efficacy and Safety of CBT on Tinnitus · NA · completed
NCT05704621 — Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05258708 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University Guro Hospital
Last refreshed: 28 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05258708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing